Hodgkin Lymphoma Treatment Market: Global Industry Analysis and Forecast (2023-2029)

Hodgkin Lymphoma Treatment Market size was valued at US$ 8.30 Bn. in 2022 and the total revenue is expected to grow at 8.3% through 2023 to 2029, reaching nearly US$ 14.51 Bn.

Hodgkin Lymphoma Treatment Market Overview:

Hodgkin's lymphoma, often known as Hodgkin's disease, is an immune system cancer that affects the lymphatic system. It can affect persons of any age, although it is more common in people aged 20 to 40 and those aged 55 and up. Cells in the lymphatic system grow improperly in Hodgkin's lymphoma and can spread outside of it. One of the two most frequent kinds of lymphatic cancer is Hodgkin's lymphoma. Non-lymphoma, Hodgkin's on the other hand, is significantly more prevalent. Advances in Hodgkin's lymphoma diagnosis and therapy have given persons with the disease a better chance of a full recovery. The prognosis for persons with Hodgkin's lymphoma is improving.Hodgkin Lymphoma Treatment MarketTo know about the Research Methodology :- Request Free Sample Report

Market Dynamics:

Reed-Sternberg cells, multinucleated large cells originating from B-lymphocytes, and accompanying aberrant, smaller mononuclear cells arising from B-lymphocytes in the germinal centers of lymphoid tissue are histologically characteristic of cancer. According to global data, there are 2.6 new cases of Hodgkin's lymphoma for every 100,000 men and women diagnosed each year. Unlike most cancers, the risk of Hodgkin's lymphoma does not rise with age; nonetheless, it is shown to be particularly high in two age groups: young adults and the elderly. The market for Hodgkin's lymphoma treatment is likely to be driven by an increase in the number of new cases identified each year. Incidences of Hodgkin lymphoma have increased, as has the availability of standard diagnostic technologies such as CT scans and X-rays. Biopsy, blood testing, and bone marrow allow for a quicker diagnosis of Hodgkin lymphoma. Hence, advanced treatment options and the high disposable income of individuals are likely to boost the growth of the market in the forecast period. further, government initiatives and health awareness programs by private organizations are simultaneously supplementing the growth of the market forward. Hodgkin Lymphoma accounted for 83,087 cases worldwide in 2021, according to Globocan figures, while the number of fatalities from Hodgkin lymphoma was reported to be around 23, 376. During the projected period, these factors are expected to boost the global Hodgkin Lymphoma Treatment Market.

Hodgkin Lymphoma Treatment Market Segment Analysis:

The Radiation Therapy segment is dominating the Treatment Type segment of the Hodgkin Lymphoma Treatment Market:

The Hodgkin Lymphoma Treatment market is further divided into Chemotherapy, Radiotherapy, and Other Treatment Types. Radiotherapy is dominating the growth of the market. It is a well-established method of killing Hodgkin's disease cells by delivering high-energy beams or particles from a source outside the body, such as external beam radiation, or from within the body, such as brachytherapy. Radiotherapy is frequently used following chemotherapy in classic Hodgkin's disease, especially when the tumor mass is large or bulky. According to the American Cancer Society, around 8,110 persons were diagnosed with Hodgkin lymphoma in the United States in 2019. Chemotherapy is the most common treatment for Hodgkin lymphoma, and innovation leading to the creation of chemotherapy medication combinations is another factor expected to drive the market over the projected period. During the forecast period, FDA approval of chemotherapeutic medicines for the treatment of Hodgkin lymphoma is expected to enhance the market.

Regional Insights:

North America is estimated to dominate the growth of the Hodgkin Lymphoma Treatment Market. In North America, the Hodgkin lymphoma therapy market is predicted to have the greatest share. Hodgkin's lymphoma claimed the lives of almost 1,000 persons (410 women and 590 men) in the United States in 2019, as per the American Cancer Society Hodgkin's lymphoma and affects both children and adults. In 2021, the number of new cases is expected to rise to roughly 8,830, with 960 deaths predicted to be recorded. These figures are expected to improve Hodgkin's lymphoma treatment in the region. It is the most common cancer among teenagers between the ages of 15 and 19. Owing to the increasing number of new cases and improved healthcare infrastructure, and technological advancement the market is developing and advancing the various treatment option. Furthermore, throughout the forecast period, increased awareness of Hodgkin lymphoma and available treatments is expected to boost the market in the region. Shortly, ongoing research and development, as well as innovation in chemotherapy and radiography treatment, are expected to enhance the market in North America. The objective of the report is to present a comprehensive analysis of the market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the market dynamics, structure by analyzing the market segments and projecting the Hodgkin Lymphoma Treatment Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the market make the report investor’s guide.

Hodgkin Lymphoma Treatment Market Scope: Inquire before buying

Global Hodgkin Lymphoma Treatment Market
Report Coverage Details
Base Year: 2022 Forecast Period: 2023-2029
Historical Data: 2018 to 2022 Market Size in 2022: US $ 8.30 Bn.
Forecast Period 2023 to 2029 CAGR: 8.3% Market Size in 2029: US $ 14.51 Bn.
Segments Covered: by Treatment Type Chemotherapy Radiotherapy Others

Hodgkin Lymphoma Treatment Market, by Region

North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina and Rest of South America)

Hodgkin Lymphoma Treatment Market Key Players are:

1. Actiza Pharmaceutical Private Limited 2. Baxter International Inc. 3. Biogen 4. Fresenius Kabi LLC 5. F. Hoffmann-La Roche Ltd 6. LGM Pharma 7. Mylan Pharmaceuticals Inc. 8. Novartis AG 9. Pfizer, Inc. 10.Teva Pharmaceuticals 11.Takeda Pharmaceutical Company Limited 12.Bristol-Myers Squibb Company 13.Baxter International Inc. 14.Merck & Co. Inc

FAQs:

1. What is the Hodgkin Lymphoma Treatment market value in 2022? Ans: Hodgkin Lymphoma Treatment market value in 2022 was estimated as 8.30 Billion USD. 2. What is the Hodgkin Lymphoma Treatment market growth? Ans: The market is anticipated to grow with a CAGR of 8.3% in the forecast period and is likely to reach USD 14.51 Billion by the end of 2029. 3. Which Treatment Type segment is expected to dominate the Hodgkin Lymphoma Treatment market during the forecast period? Ans: The Radiotherapy segment is dominating the growth of the market. It is a well-established method of killing Hodgkin's disease cells by delivering high-energy beams or particles from a source outside the body, such as external beam radiation, or from within the body, such as brachytherapy. 4. Who are the key players in the Hodgkin Lymphoma Treatment market? Ans: Some key players operating in the market include Actiza Pharmaceutical Private Limited, Baxter International Inc., Biogen, Fresenius Kabi LLC, F. Hoffmann-La Roche Ltd, LGM Pharma, Mylan Pharmaceuticals Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals, Takeda Pharmaceutical Company Limited. 5. What is the key driving factor for the growth of the Hodgkin Lymphoma Treatment market? Ans: Key factors that are driving the market growth include an increase in incidences of Hodgkin lymphoma and the availability of standard diagnostic tools such as CT scans, X-rays. Biopsy, blood tests, bone marrow enable faster diagnosis of the Hodgkin lymphoma condition.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Hodgkin Lymphoma Treatment Market Size, by Market Value (US$ Bn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2022 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Hodgkin Lymphoma Treatment Market 3.4. Geographical Snapshot of the Hodgkin Lymphoma Treatment Market, By Manufacturer share 4. Hodgkin Lymphoma Treatment Market Overview, 2022-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porter Five Forces Analysis 4.1.6.1. The threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. The threat of Substitute Grades 4.1.6.5. The intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Hodgkin Lymphoma Treatment Market 5. Supply Side and Demand Side Indicators 6. Hodgkin Lymphoma Treatment Market Analysis and Forecast, 2022-2029 6.1. Hodgkin Lymphoma Treatment Market Size & Y-o-Y Growth Analysis. 7. Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 7.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 7.1.1. Chemotherapy 7.1.2. Radiotherapy 7.1.3. Others 8. Hodgkin Lymphoma Treatment Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2022-2029 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 9.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 9.1.1. Chemotherapy 9.1.2. Radiotherapy 9.1.3. Others 10. North America Hodgkin Lymphoma Treatment Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 11.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 12. Canada Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 12.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 13. Mexico Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 13.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 14. Europe Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 14.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 15. Europe Hodgkin Lymphoma Treatment Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 16.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 17. France Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 17.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 18. Germany Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 18.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 19. Italy Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 19.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 20. Spain Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 20.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 21. Sweden Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 21.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 22. CIS Countries Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 22.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 23. Rest of Europe Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 23.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 24. Asia Pacific Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 24.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 25. Asia Pacific Hodgkin Lymphoma Treatment Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 26.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 27. India Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 27.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 28. Japan Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 28.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 29. South Korea Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 29.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 30. Australia Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 30.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 31. ASEAN Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 31.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 32. Rest of Asia Pacific Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 32.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 33. Middle East Africa Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 33.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 34. Middle East Africa Hodgkin Lymphoma Treatment Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 35.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 36. GCC Countries Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 36.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 37. Egypt Textile Reinforced Concrete e-Market Analysis and Forecasts, 2022-2029 37.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 38. Nigeria Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 38.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 39. Rest of ME&A Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 39.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 40. South America Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 40.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 41. South America Hodgkin Lymphoma Treatment Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 42.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 43. Argentina Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 43.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 44. Rest of South America Hodgkin Lymphoma Treatment Market Analysis and Forecasts, 2022-2029 44.1. Market Size (Value) Estimates & Forecast By Treatment Type, 2022-2029 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Hodgkin Lymphoma Treatment Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Grades, and R&D Investment 45.2.2. New Grade Launches and Grade Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment, and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 45.3. Company Profile: Key Players 45.3.1. Novartis AG 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Grade Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Development 45.3.2. Actiza Pharmaceutical Private Limited 45.3.3. Baxter International Inc. 45.3.4. Biogen 45.3.5. Fresenius Kabi LLC 45.3.6. F. Hoffmann-La Roche Ltd 45.3.7. LGM Pharma 45.3.8. Mylan Pharmaceuticals Inc. 45.3.9. Novartis AG 45.3.10. Pfizer, Inc. 45.3.11. Teva Pharmaceuticals 45.3.12. Takeda Pharmaceutical Company Limited 45.3.13. Bristol-Myers Squibb Company 45.3.14. Baxter International Inc. 45.3.15. Merck & Co. Inc. 46. Primary Key Insights
  • INQUIRE BEFORE BUYING